Alkermes plc

Alkermes plc is a biopharmaceutical company that researches, develops, and commercializes pharmaceutical products to address unmet medical needs in therapeutic areas globally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, and bipolar I disorder. Its marketed products include ARISTADA, an intramuscular injectable suspension for schizophrenia; ARISTADA INITIO for schizophrenia in adults; VIVITROL for alcohol dependence and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic for schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension for cataplexy or excessive daytime sleepiness in pediatric patients. Alkermes also licenses its proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products.

Alkermes plc is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ALKS. The company's stock is traded in US Dollars (USD), as it is listed on a US-based exchange. Despite being headquartered in Dublin, Ireland, the company's primary listing is in the United States, reflecting its significant operations and market presence in the US.

Alkermes plc operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This means the company is involved in the research, development, and production of pharmaceutical drugs, focusing on specialty areas such as central nervous system disorders and addiction treatments. As a specialty and generic drug manufacturer, Alkermes develops both branded and generic medications, with a particular emphasis on addressing unmet medical needs in therapeutic areas like opioid dependence, alcohol dependence, schizophrenia, and bipolar I disorder.

Alkermes plc is headquartered in Dublin, Ireland, and serves markets globally. The company was founded in 1987 and has a strong presence in the United States, as evidenced by its listing on the NasdaqGS and its collaboration agreements with US-based companies like Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes' products address unmet medical needs in therapeutic areas worldwide, with a focus on neurological disorders and addiction treatments.

Alkermes has a portfolio of proprietary commercial products targeting central nervous system disorders. Key products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia, and ARISTADA INITIO, also for schizophrenia in adults. VIVITROL is used for the treatment of alcohol dependence and the prevention of opioid dependence. LYBALVI is an oral atypical antipsychotic for adults with schizophrenia and bipolar I disorder. LUMRYZ is an extended-release oral suspension for the treatment of cataplexy or excessive daytime sleepiness in pediatric patients. Additionally, the company licenses its proprietary technology platforms to third parties for product development and manufacturing.